连续血糖监测:妊娠期糖尿病后临床肥胖型2型糖尿病的诊断标准
在英国国王学院医院开展的多提案队列研究,纳入1118名产后女性,比较连续血糖监测(CGM)与美国糖尿病协会(ADA)标准对妊娠期糖尿病后临床肥胖型2型糖尿病的诊断。产后5个月,CGM诊断8.9%(48/539),ADA标准诊断4.3%(23/539);仅CGM诊断的35例心血管代谢 profile 更差,其中26例1年随访时平均血糖仍≥131.5 mg/dL。结论认为CGM优于ADA标准。
要点
- 产后5个月,CGM诊断临床肥胖型2型糖尿病8.9%(48/539),ADA标准诊断4.3%(23/539)。
- 仅CGM诊断的35例心血管代谢 profile 较仅ADA诊断的10例更差。
- 仅CGM诊断的35例中26例1年随访时平均血糖仍≥131.5 mg/dL且心血管代谢异常。
核心结论
- 妊娠期糖尿病女性的产后随访不仅应关注血糖异常,还应关注其心血管代谢 profile。
- 在此方面,连续血糖监测在诊断临床肥胖型2型糖尿病上优于美国糖尿病协会标准。
研究设计与样本
- 2023年9月至2025年4月在英国伦敦国王学院医院开展的多提案队列研究。
- 邀请连续入组的妊娠期糖尿病女性和非妊娠期糖尿病女性在产后5个月参与,妊娠期糖尿病患者另邀1年随访门诊。
- 进行为期10天的盲法连续血糖监测(Dexcom G7;Dexcom,圣迭戈,加利福尼亚州)。
- 共检查1118名女性,包括276名(24.7%)产后5个月非妊娠期糖尿病对照、539名(48.2%)产后5个月妊娠期糖尿病后女性、303名(27.1%)产后1年妊娠期糖尿病后女性。
主要发现
- 非妊娠期糖尿病组的平均血糖+2个标准差为≥131.5 mg/dL。
- 产后5个月妊娠期糖尿病组中,连续血糖监测将8.9%(48/539)的女性分类为临床肥胖型2型糖尿病,美国糖尿病协会标准的相应值为4.3%(23/539)。
- 仅由连续血糖监测诊断而美国糖尿病协会标准未诊断的女性(n=35)心血管代谢 profile 较仅由美国糖尿病协会标准诊断的女性(n=10)更差。
- 35例仅由连续血糖监测分类的额外病例中,26例参加了产后1年门诊,所有患者连续血糖监测平均血糖仍≥131.5 mg/dL且心血管代谢 profile 异常。
关键数值与推荐
- 美国糖尿病协会标准定义:糖化血红蛋白≥6.5%、空腹血浆葡萄糖≥126 mg/dL或2小时口服葡萄糖耐量试验≥200 mg/dL。
- 连续血糖监测标准定义:平均血糖≥131.5 mg/dL,即本非妊娠期糖尿病组平均血糖+2个标准差。
- 临床肥胖定义采用近期发表的《柳叶刀糖尿病与内分泌学委员会》标准:过量体脂直接影响器官和组织功能。
临床怎么用
- 妊娠期糖尿病女性产后随访应同时关注血糖异常和心血管代谢 profile。
- 连续血糖监测在诊断临床肥胖型2型糖尿病方面优于美国糖尿病协会标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosis of dysglycemia is traditionally based on classical criteria, such as those outlined by the American Diabetes Association (ADA), which rely on isolated glucose measurements. However, these static assessments may not fully capture an individual's dynamic glycemic profile. Continuous glucose monitoring (CGM) offers an alternative approach that provides a more comprehensive and accurate reflection of glycemic status over time. Women with a history of gestational diabetes mellitus (GDM) represent a particularly high-risk group. Compared with women who maintained normoglycemia during pregnancy, those with prior GDM have a significantly increased risk of developing dysglycemia. In addition to altered glucose metabolism, they frequently exhibit a cluster of cardiometabolic abnormalities, including obesity, dyslipidemia, hypertension, and early cardiac dysfunction. OBJECTIVE: To compare continuous glucose monitoring to American Diabetes Association criteria, in the postpartum period in women who had developed gestational diabetes mellitus during their recent pregnancy, for diagnosis of type 2 diabetes mellitus complicated by clinical obesity. STUDY DESIGN: Between September 2023 and April 2025, we conducted a multiproposal cohort study at King's College Hospital, London, UK. We invited consecutive women with and without gestational diabetes mellitus at 5 months postpartum. Gestational diabetes mellitus patients were also invited for a 1-year follow-up clinic. Blinded continuous glucose monitoring (Dexcom G7; Dexcom, San Diego, CA) was performed for 10 days. The primary outcome was type 2 diabetes mellitus with clinical obesity, defined by first, the American Diabetes Association criteria (hemoglobin A1c ≥6.5%, fasting plasma glucose ≥126 mg/dL, or 2-hour oral glucose tolerance test of ≥200 mg/dL), and second, continuous glucose monitoring average glucose ≥131.5 mg/dL, which is the mean+2 standard deviation of our nongestational diabetes mellitus group. Clinical obesity was defined by the recently published The Lancet Diabetes and Endocrinology Commission, as excess body fat directly affecting the function of organs and tissues. RESULTS: We examined 1118 women, including 276 (24.7%) nongestational diabetes mellitus controls at 5 months postpartum, 539 (48.2%) postgestational diabetes mellitus at 5 months postpartum, and 303 (27.1%) postgestational diabetes mellitus at 1 year postpartum. In the nongestational diabetes mellitus group, the mean+2 standard deviation average glucose was ≥131.5 mg/dL. At 5 months postpartum in the gestational diabetes mellitus group, continuous glucose monitoring classified 8.9% (48/539) women as diabetes mellitus type 2 with clinical obesity and the respective value by the American Diabetes Association criteria was 4.3% (23/539). Women diagnosed by continuous glucose monitoring but not the American Diabetes Association criteria (n=35) had a worse cardiometabolic profile than those diagnosed by the American Diabetes Association criteria alone (n=10). Of the 35 additional cases, classified only by continuous glucose monitoring, 26 attended to the 1-year postnatal clinic and all still had an average glucose ≥131.5 mg/dL measured by continuous glucose monitoring and abnormal cardiometabolic profile. CONCLUSION: Postpartum follow-up in women who had gestational diabetes mellitus should not only focus on dysglycemia but also on their cardiometabolic profile. In this respect, continuous glucose monitoring is superior to American Diabetes Association criteria for diagnosis of diabetes mellitus type 2 with clinical obesity.
引用
- Gómez Fernández C, Mitsigiorgi R, Fochini M, et al. Continuous glucose monitoring: criteria for the diagnosis of type 2 diabetes mellitus with clinical obesity after gestational diabetes. Am J Obstet Gynecol. 2025. PMID: 40975255. doi:10.1016/j.ajog.2025.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。